Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in February 2016 on request of the Sponsor.

On 6 December 2012, orphan designation (EU/3/12/1082) was granted by the European Commission to B. Braun Melsungen AG, Germany, for triheptanoin for the treatment of long-chain 3-hydroxyacyl-CoA-dehydrogenase deficiency.

For a list of the administrative updates to this public summary of opinion please refer to the PDF document below.

Key facts

Active substance
Disease / condition
Treatment of long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency
Date of first decision
EU designation number

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

B. Braun Melsungen AG
Carl-Braun-Strasse 1
34212 Melsungen
Tel. +49 56 61 710
Fax +49 56 61 71 2950

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating